Fibrosis-Inflammation Lab

⌘K

Fibrosis-Inflammation Lab

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights
Resources
Pathways

Company

About
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

/

/

Efruxifermin (Efruxifermin) | Accelerate Your Fibrosis Research

Home/Drugs/Efruxifermin

Efruxifermin

Efruxifermin

Phase 3

Sponsor: Akero Therapeutics

Indication: MASH

Mechanism of Action

FGF21 Analog

Target: FGF21

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT03976401

A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Phase:PHASE2Org:Akero Therapeutics, Inc

RECRUITINGNCT06215716

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Phase:PHASE3Org:Akero Therapeutics, Inc

ACTIVE_NOT_RECRUITINGNCT06161571

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Phase:PHASE3Org:Akero Therapeutics, Inc

ACTIVE_NOT_RECRUITINGNCT05039450

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

Phase:PHASE2Org:Akero Therapeutics, Inc

RECRUITINGNCT06528314

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Phase:PHASE3Org:Akero Therapeutics, Inc

View all trials on ClinicalTrials.gov

Relevant Publications (PubMed)

Efficacy and safety of efruxifermin for patients with NASH/MASH: an updated systematic review and meta-analysis.

Xiao YJ, Liu XP, Zhang YL et al.

Front Pharmacol2025

Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction-Associated Steatohepatitis: A Network Meta-Analysis of Randomized Controlled Trials.

Jaber D, Jaber I, Lehia AA et al.

Endocrinol Diabetes Metab2026 May

Clinical and metabolic benefits of efruxifermin in MASH: a GRADE-assessed meta-analysis of randomized trials with trial sequential analysis.

Rajab I, Emara A, Elgendy MS et al.

Hepatol Int2026 Mar 17

Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions.

Patil R, Dunn W, Noureddin M et al.

Drugs2026 May

Efficacy and Safety of Efruxifermin in Patients With MASH: A Meta-Analysis of Randomized Controlled Trials.

Gastroenterol Hepatol (N Y)2025 Nov

View more on PubMed

Validated Models

This drug has been validated in the following preclinical models: